Correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic Fibrosis in MASlD With type2 Diabetes Mellitus

November 28, 2024 updated by: Elzahraa Kadry Mohamed, Sohag University

Correlation Between Serum Adiponectin and Resistin Levels and Degree of Hepatic Fibrosis In Metabolic Dysfunction _Associated Steatotic Liver Disease (MASLD)With Type2 Diabetes Mellitus

Metabolic dysfunction asociated steatotic liver disease prevalence is 25%world wide diabetic patients have a risk for MASLD then have hepatic fibrosis so we study correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic fibrosis In Metabolic dysfunction asociated steatotic liver disease in patients with type2 Diabetes Mellitus

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Usama M Abdelaal, Professor
  • Phone Number: 01065962094

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

MASLD patients with hepatic fibrosis groupA,MASLD patients without hepatic fibrosis

Description

Inclusion Criteria:

  • patients of both sex who have type2 Diabetes Mellitus for less than five years

Exclusion Criteria:alcholics ,chronic liver disease elevated liver functions , sever infection

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
MASLD patients with hepatic fibrosis
MASLD with hepatic fibrosis with type 2 diabetes mellitus
Diagnostic test: serum Adiponectine and Resistin
corrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis
Diagnostic test: fibroscan
hepatic fibrosis detection in type 2 diabetes mellutis
MASLD without hepatic fibrosis
MASLD with out hepatic fibrosis with type 2 diabetes mellutis
Diagnostic test: serum Adiponectine and Resistin
corrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis
Diagnostic test: fibroscan
hepatic fibrosis detection in type 2 diabetes mellutis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
degree of hepatic fibrosis in MASLD with type 2 diabetes mellitus
Time Frame: 1 year
adiponectineand resistine level with degree of hepatic fibrosis in MASLD pt. with type 2 DM
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2024

Primary Completion (Estimated)

December 1, 2025

Study Completion (Estimated)

December 30, 2025

Study Registration Dates

First Submitted

November 28, 2024

First Submitted That Met QC Criteria

November 28, 2024

First Posted (Estimated)

December 4, 2024

Study Record Updates

Last Update Posted (Estimated)

December 4, 2024

Last Update Submitted That Met QC Criteria

November 28, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med-24-11--5MD

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatic Fibrosis

Clinical Trials on serum Adiponectine and Resistin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe